eShowcase: Nextrials and Vitalograph
Partnership puts pulmonary data in the hands of researchers when and where they need it
Partnership puts pulmonary data in the hands of researchers when and where they need it
Nextrials, Inc. (San Ramon, CA) is partnering with Vitalograph (Lenexa, KS, and Buckingham, UK) to deliver expedited access to pulmonary function data collected during clinical trials. The system works by closely integrating Nextrials' Prism clinical trial management system with the Vitalograph Spirotrac Centralized Spirometry System.
As a result, biotechnology and medical device researchers can quickly evaluate pulmonary lung function, potentially improving patient safety. For researchers, real-time access to study data also translates into enhanced workflow and efficiency. Ultimately, this results in reduced costs and quicker time to market for new therapies. As a result of the collaboration, sponsors have access to a single product that provides all relevant data including pulmonary function information, in real time across multiple test sites and multiple studies.
Nextrials, Inc., (925) 355-3000, www.nextrials.com
Vitalograph, (800) 255-6626, www.vitalograph.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
